Most patients with newly diagnosed focal epilepsy continue to experience seizures for at least one year after starting antiseizure medication (ASM) therapy.
About 23% of patients develop treatment resistance within the first year, as defined by failure to respond to two adequate ASM trials.
Median time to seizure freedom is approximately 12 months, indicating a prolonged adjustment period necessary for optimal seizure control.
Prognostic factors for resistance include a history of psychiatric disorders and high pretreatment seizure frequency.
Study Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
